Background Fragments of parathyroid hormone (PTH) have been identi ed (amino acids 7--84) which may interfere with commercially available 'intact molecule' PTH assays. Novel assays which employ an antibody directed to the rst seven amino acids of the N-terminus of PTH are thought to be free from cross-reactivity with the 7--84 fragments, and therefore measure true 'whole molecule' PTH. Transplant recipients (as well as those in end-stage renal failure) have been reported to have elevated levels of 'intact' in comparison with 'whole molecule' PTH.
Introduction
Biologically active parathyroid hormone (PTH) is present in the human circulation predominantly as a peptide of 1^84 amino acids. Fragmentation of this intact hormone in vivo has been well described and has been the stimulus to the development of immunoassays speci¢c to the intact molecule. 1 These modern commercial assays utilize two antibodies, with one antibody targeting the N-terminal and the other the mid-molecule, resulting in an intact molecule assay. Recent publications, however, have identi¢ed the presence of a 7^84 fragment which may interfere with the intact PTH assays and is thought to accumulate to a greater degree in patients with renal failure. 2 This results in falsely elevated results by a factor of 2^2¢5 in most commercial assays, 3 with a progressive increase being reported as glomerular ¢ltration rate decreases. 4 The identi¢cation of this circulating fragment has led to the development of assays that utilize an antibody to the 1^7 region of the PTH molecule, combined with a common antibody to the 39^84 region, thus eliminating cross-reactivity from 7^84 fragments. The 1^84 molecule has been termed cyclase activating PTH (CAP) or`whole molecule' PTH.
We aimed to compare the results obtained by`whole molecule' and intact PTH assays in two populations of renal transplant recipients: one group with hyperparathyroidism, the other with adynamic bone disease. From the data obtained, we aimed to establish whether a`whole molecule' PTH assay gave a better indication of which patients su¡ered from adynamic bone disease. The data obtained from studies utiliz ing whole molecule'assays have previously demonstrated that`whole molecule' PTH values are signi¢cantly lower than those for intact PTH. 2^5 We also investigated whether this di¡erence varies within a sample population or whether the decrease is uniform. No variation would suggest merely that the two types of assay simply have di¡erent population reference ranges.
It might be expected that renal transplant recipients with relatively normal renal function would have lower rates of accumulation of the 7^84 fragments. However, as described in end-stage renal failure, higher PTH levels have recently been observed using the intact assay versus the`whole molecule'assay in a population of 14 renal transplant recipients. 6 The origin of this fragment has been proposed to be the parathyroid gland itself. 6 
Materials and methods
Serum samples (nˆ28) were obtained from nonfasting female renal transplant recipients who had previously been classi¢ed as having hyperparathyroid (nˆ14) or adynamic bone disease (nˆ14) based on previously published transiliac crest bone biopsy ¢nd-ings. 7 This was a histological classi¢cation, with hyperparathyroidism being classed as the presence of two out of three of the following: increased eroded bone surfaces, elevated osteoclast surface and increased osteoclast numbers. In the adynamic bone disease group, measurements of osteoblast surface, osteoid thickness and osteoclast numbers were all within or below the reference range for age-and gender-matched controls. 7 Samples were transported to the laboratory via vacuum tube, separated immediately upon receipt, and then stored frozen at 7708C until analysis. All samples had been obtained following informed consent and local ethical committee approval.
Each sample was assayed for intact PTH by the DPC Immulite 2000 automated immunoassay (Diagnostic Products Corporation, Los Angeles CA, USA) and by the Scantibodies total PTH immunoradiometric assay kit (Scantibodies Laboratory Inc., Santee CA, USA). Whole molecule' (CAP) PTH was assayed by the Scantibodies CAP radioimmunoassay kit (Scantibodies Laboratory Inc). All three assays use human serum based calibrators with a calibration range in excess of 2000 ng/L. Serum creatinine concentrations were measured using an Olympus AU600 analyser (Olympus Diagnostic Systems, Southall, UK).
Results and discussion
The results (see Fig. 1) show that there is a good correlation between the two assays in the measurement of intact/total PTH and the`whole molecule' (CAP) PTH over a wide range of PTH concentrations. Spearman rank correlations were calculated for the graphs illustrated in Fig. 1a (P50¢0001) and Fig. 1b (P50¢0001) , and Passing and Bablock regression analysis showed no major deviation between methods.Wilcoxon signed rank tests showed`whole molecule' PTH (CAP) values to be signi¢cantly lower than those obtained by both the DPC intact PTH assay (P50¢0001) and the Scantibodies total PTH assay (P50 ¢ 0001). The di¡er-ence between the intact and the`whole molecule' measurements appears to be uniform across both histological groups.`Whole molecule' PTH (CAP) values were on average 36% lower than DPC intact PTH results and 32% lower than Scantibodies total PTH results. For all subjects the mean (+standard deviation, SD)`whole molecule' PTH (CAP) was 48¢7 ng/L (+53¢9) compared with the DPC intact assay which had a mean of 83¢5 ng/L (+88¢1) and the Scantibodies total PTH assay which had a mean of 80¢5 ng/L (+92¢4). No di¡erence was observed between the values obtained by the DPC intact PTH chemiluminescence assay and the Scantibodies total PTH immunoradiome tric assay (Pˆ0¢214). The mean serum creatinine concentration of all subjects was 122 (+37) mmol/L.
DPC give a reference range of 8^78 ng/L for their intact PTH assay; Scantibodies quote 9^63 ng/L for their total PTH assay and 5^39 ng/L for their`whole molecule' (CAP) assay. The di¡erence in the reference ranges is re£ected in Fig. 1 , in which, despite a good correlation being illustrated, the correlation line is shifted upwards, away from unity.
Within our two sample populations, the results re£ected the published reference ranges for each assay, with`whole molecule' PTH results signi¢cantly lower than the intact PTH measurements. This was illustrated by the statistically signi¢cant correlation between methods. This would suggest that, if a circulating PTH fragment is present in the serum of renal transplant patients and interferes with intact PTH assays, its presence is in uniform concentrations between individuals. This is re£ected in lower reference ranges for`whole molecule' PTH (CAP) in comparison with intact PTH. It has been previously reported that`whole molecule' assays may also enable the easier identi¢cation of those patients with adynamic bone disease. 5 The use of intact PTH/`whole molecule' (CAP) ratios has been proposed to be a more powerful predictor of high and low bone turnover, with a ratio of 41 being reported as indicative of high/ normal bone turnover in a group of dialysis patients. 8 We investigated this in our two populations and found no signi¢cant di¡erence in the ratios between populations using both intact PTH assays and the`whole molecule' (CAP) assay. The adynamic population gave a mean (SD) ratio of 1¢49 (+0¢41) when the Scantibodies total PTH assay was used and a mean ratio of 1¢66 (+0¢42) when the DPC intact PTH assay was used. The hyperparathyroid population gave a mean ratio of 1¢63 (+0¢36) with the Scantibodies total PTH assay and a mean ratio of 1¢73 (+0¢48) with the DPC intact PTH assay.
Conclusion
There is evidence to suggest that the use of an antibody to the1^7 amino acid region of the PTH molecule yields results that are signi¢cantly lower than those obtained by intact PTH assays. However, this change is uniform across a sample population of renal transplant recipients with hyperparathyroid or adynamic bone disease. We conclude that the use of`whole molecule' assays that include an antibody to the 1^7 region of the PTH molecule will provide very little additional clinical information to that obtained from intact PTH assays if the appropriate reference ranges are employed for these individuals. 
